Literature DB >> 17227294

Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.

B Zsebik1, K Symonowicz, Y Saleh, P Ziolkowski, A Bronowicz, G Vereb.   

Abstract

OBJECTIVES: Photodynamic therapy (PDT) and inhibition of cathepsin B proteases by cystatin (cysteine proteinase inhibitor, CPI) are potential new tumour treatment modalities. We have investigated the efficacy of PDT and CPI alone and in combination on a solid mammary carcinoma transplanted into Wistar rats.
MATERIALS AND METHODS: Intraperitoneally injected single doses of chlorine e6 or HpD as photosensitizers were excited at 630 nm (90 J/cm(2)). CPI (500 micro g per animal) was injected around the tumour daily during the 8-day treatment. Inoculation of tumour was either on day 1 of the protocol, or 8 days before. On day 8, tumour size was measured, tumour necrosis and vascularization were determined based on haematoxylin and eosin (H&E)-stained sections and serum vascular endothelial growth factor (VEGF) levels measured using an enzyme-linked immunosorbent assay kit.
RESULTS: No differences (two-way anova) were found for treatments started with various time lags. At doses where CPI or PDT alone had no or negligible effect, their combination caused a marked (P < 0.001) decrease in serum VEGF, paralleled by a significant decrease in tumour size and number of capillary vessels, and a significant increase in necrosis (up to 80% of the tumour tissue).
CONCLUSIONS: The combination of PDT and CPI could be a useful approach in tumour therapy as the two agents appear to be synergistic and probably decrease VEGF production by the tumour tissue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17227294      PMCID: PMC6496468          DOI: 10.1111/j.1365-2184.2007.00420.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  34 in total

Review 1.  Photodynamic therapy: a new concept in medical treatment.

Authors:  C H Sibata; V C Colussi; N L Oleinick; T J Kinsella
Journal:  Braz J Med Biol Res       Date:  2000-08       Impact factor: 2.590

2.  Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host.

Authors:  Charlotte Kopitz; Martina Anton; Bernd Gansbacher; Achim Krüger
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

3.  Determination of vascular-endothelial growth factor levels in serum from tumor-bearing BALB/c mice treated with photodynamic therapy.

Authors:  Beata J Osiecka; Piotr Ziołkowski; Elzbieta Gamian; Anna Lis-Nawara; Stephen G White; Raymond Bonnett
Journal:  Med Sci Monit       Date:  2003-04

4.  Photodynamic treatment of epithelial tissue derived from patients with endometrial cancer: a contribution to the role of laminin and epidermal growth factor receptor in photodynamic therapy.

Authors:  P Ziółkowski; K Symonowicz; B J Osiecka; J Rabczyn Ski; J Gerber
Journal:  J Biomed Opt       Date:  1999-07       Impact factor: 3.170

Review 5.  Proteases in gastrointestinal neoplastic diseases.

Authors:  L Herszényi; M Plebani; P Carraro; M De Paoli; G Roveroni; R Cardin; F Foschia; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Chim Acta       Date:  2000-02-15       Impact factor: 3.786

Review 6.  Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection.

Authors:  Kristjan Plaetzer; Tobias Kiesslich; Christian Benno Oberdanner; Barbara Krammer
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

7.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

Review 8.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

9.  Dual role of tumor necrosis factor-alpha in angiogenesis.

Authors:  L F Fajardo; H H Kwan; J Kowalski; S D Prionas; A C Allison
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

10.  Release of cytochrome c and activation of pro-caspase-9 following lysosomal photodamage involves Bid cleavage.

Authors:  J J Reiners; J A Caruso; P Mathieu; B Chelladurai; X-M Yin; D Kessel
Journal:  Cell Death Differ       Date:  2002-09       Impact factor: 15.828

View more
  3 in total

1.  Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

Authors:  Karan Arora; Mackenzie Herroon; Malik H Al-Afyouni; Nicholas P Toupin; Thomas N Rohrabaugh; Lauren M Loftus; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

2.  P18 peptide, a functional fragment of pigment epithelial-derived factor, inhibits angiogenesis in hepatocellular carcinoma via modulating VEGF/VEGFR2 signalling pathway.

Authors:  Xin Wang; Peng Xiu; Fuhai Wang; Jingtao Zhong; Honglong Wei; Zongzhen Xu; Feng Liu; Jie Li
Journal:  Oncol Rep       Date:  2017-06-14       Impact factor: 3.906

3.  Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer.

Authors:  Yunxia Ma; Yuan Chen; Yong Li; Katja Grün; Alexander Berndt; Zhongwei Zhou; Iver Petersen
Journal:  Oncotarget       Date:  2017-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.